The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Trial Profile

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FLINT
  • Most Recent Events

    • 24 Oct 2017 Results (n=188) of lipoprotein analysis presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 15 Sep 2017 Results of post-hoc analysis presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 12 Jun 2017 Data from the retrospective analysis of this trial published in an Intercept Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top